JP2014520856A5 - - Google Patents

Download PDF

Info

Publication number
JP2014520856A5
JP2014520856A5 JP2014520335A JP2014520335A JP2014520856A5 JP 2014520856 A5 JP2014520856 A5 JP 2014520856A5 JP 2014520335 A JP2014520335 A JP 2014520335A JP 2014520335 A JP2014520335 A JP 2014520335A JP 2014520856 A5 JP2014520856 A5 JP 2014520856A5
Authority
JP
Japan
Prior art keywords
composition
administered
riluzole
combination
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014520335A
Other languages
English (en)
Japanese (ja)
Other versions
JP6145946B2 (ja
JP2014520856A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/046523 external-priority patent/WO2013010015A2/en
Publication of JP2014520856A publication Critical patent/JP2014520856A/ja
Publication of JP2014520856A5 publication Critical patent/JP2014520856A5/ja
Application granted granted Critical
Publication of JP6145946B2 publication Critical patent/JP6145946B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014520335A 2011-07-13 2012-07-12 併用als療法 Expired - Fee Related JP6145946B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201161507381P 2011-07-13 2011-07-13
US61/507,381 2011-07-13
US201161544533P 2011-10-07 2011-10-07
US61/544,533 2011-10-07
US201261637759P 2012-04-24 2012-04-24
US201261637770P 2012-04-24 2012-04-24
US61/637,770 2012-04-24
US61/637,759 2012-04-24
US201261646699P 2012-05-14 2012-05-14
US61/646,699 2012-05-14
PCT/US2012/046523 WO2013010015A2 (en) 2011-07-13 2012-07-12 Combination als therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017090313A Division JP2017128610A (ja) 2011-07-13 2017-04-28 併用als療法

Publications (3)

Publication Number Publication Date
JP2014520856A JP2014520856A (ja) 2014-08-25
JP2014520856A5 true JP2014520856A5 (enExample) 2015-09-03
JP6145946B2 JP6145946B2 (ja) 2017-06-14

Family

ID=47506929

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014520335A Expired - Fee Related JP6145946B2 (ja) 2011-07-13 2012-07-12 併用als療法
JP2017090313A Pending JP2017128610A (ja) 2011-07-13 2017-04-28 併用als療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017090313A Pending JP2017128610A (ja) 2011-07-13 2017-04-28 併用als療法

Country Status (16)

Country Link
US (1) US10272082B2 (enExample)
EP (1) EP2731611B1 (enExample)
JP (2) JP6145946B2 (enExample)
KR (1) KR101951220B1 (enExample)
CN (2) CN109316480A (enExample)
AU (2) AU2012281042B2 (enExample)
BR (1) BR112014000742A2 (enExample)
CA (1) CA2849213A1 (enExample)
EA (2) EA201791043A1 (enExample)
HK (1) HK1197178A1 (enExample)
IL (1) IL230391B (enExample)
IN (1) IN2014DN00200A (enExample)
PH (1) PH12014500094A1 (enExample)
SG (1) SG10201605707UA (enExample)
WO (1) WO2013010015A2 (enExample)
ZA (1) ZA201400236B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
US20160263110A1 (en) * 2013-11-04 2016-09-15 Ab Science Use of masitinib for treatment of amyotrophic lateral sclerosis
LT3137622T (lt) 2014-04-29 2022-04-25 Cytokinetics, Inc. Gyvybinio pajėgumo nykimo mažinimo būdai
RS59490B1 (sr) * 2014-11-21 2019-12-31 Biohaven Therapeutics Ltd Sublingvalna formulacija riluzola
CA2967659A1 (en) * 2014-11-21 2016-05-26 Biohaven Pharmaceutical Holding Company Ltd. Sublingual administration of riluzole
EP3072513A1 (en) * 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
EA038531B1 (ru) 2016-03-25 2021-09-10 Аб Сьянс Способ лечения амиотрофного латерального склероза, применение фармацевтической композиции, содержащей мазитиниб
EP4031135A4 (en) 2019-09-20 2023-10-18 Icahn School of Medicine at Mount Sinai CONTROLLED RELEASE FORMULATIONS OF RILUZOLE AND USES THEREOF

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3507866A (en) 1967-08-08 1970-04-21 Merck & Co Inc 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation
BE788065A (fr) 1971-08-26 1973-02-26 Degussa Nouvelles aza-benzimidazoles et procede pour leur preparation
IT1156732B (it) 1978-05-10 1987-02-04 Roussel Maestretti Spa Derivati sostituiti dell'1,3-diidroimidazo(4,5-b)piridin-2-one e relativo procedimento di produzione
US4668686A (en) 1985-04-25 1987-05-26 Bristol-Myers Company Imidazoquinoline antithrombrogenic cardiotonic agents
US4775674A (en) 1986-05-23 1988-10-04 Bristol-Myers Company Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors
US4943573A (en) 1989-11-01 1990-07-24 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility
US5354759A (en) 1991-09-12 1994-10-11 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic compounds
JPH0641135A (ja) 1992-07-21 1994-02-15 Nippon Soda Co Ltd イミダゾプテリジン誘導体及びその製造方法
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
AU4231299A (en) 1998-06-04 1999-12-20 Abbott Laboratories Cell adhesion-inhibiting antinflammatory compounds
KR100756592B1 (ko) 1999-10-08 2007-09-10 그뤼넨탈 게엠베하 비사이클릭 이미다조-3-일-아민 유도체, 이의 제조방법 및 이를 포함하는 진통제
HUP0203140A3 (en) 1999-10-08 2004-06-28 Gruenenthal Gmbh Bicyclic imidazo-5-yl-amine derivatives, process for their preparation and pharmaceutical compositions containing them
DE10050663A1 (de) 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
US20040235801A1 (en) * 2001-10-25 2004-11-25 Jean-Pierre Julien Therapy for stroke
US20030083318A1 (en) 2001-10-25 2003-05-01 Jean-Pierre Julien Therapy for neurodegenerative diseases
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
GB0212048D0 (en) 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
US20040166137A1 (en) 2002-11-08 2004-08-26 Lackey John William Hetero-substituted benzimidazole compounds and antiviral uses thereof
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
US7476665B2 (en) 2003-06-26 2009-01-13 Merck & Co., Inc. Benzodiazepine CGRP receptor antagonists
EP1646614A4 (en) 2003-07-01 2008-09-10 Merck & Co Inc OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA
EP1694323A4 (en) 2003-12-19 2009-05-13 Elixir Pharmaceuticals Inc METHOD FOR TREATING A DISEASE
EP1715855A4 (en) 2004-01-29 2010-06-16 Elixir Pharmaceuticals Inc ANTIVIRAL DRUGS
WO2005108374A1 (en) 2004-04-29 2005-11-17 Fmc Corporation Insecticidal diazole and triazole derivatives
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
AU2005289644A1 (en) 2004-09-24 2006-04-06 Janssen Pharmaceutica, N.V. Imidazo{4,5-b}pyrazinone inhibitors of protein kinases
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
CN101189238A (zh) 2005-02-16 2008-05-28 先灵公司 具有cxcr3拮抗剂活性的哌嗪-哌啶
WO2007078815A2 (en) 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2007125321A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
EP2037931A2 (en) 2006-04-25 2009-03-25 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
WO2008016648A2 (en) 2006-08-01 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
BRPI0714725B1 (pt) * 2006-08-02 2021-05-25 Cytokinetics, Inc Entidade química, composição farmaceuticamente aceitável, e, uso de uma entidade química
CN101522681B (zh) * 2006-08-02 2012-10-03 赛特凯恩蒂克公司 特定的化学个体、组合物和方法
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
ES2627352T3 (es) 2006-10-19 2017-07-27 Signal Pharmaceuticals, Llc Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas
WO2008075007A1 (en) 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
ES2547303T3 (es) 2007-01-19 2015-10-05 Ardea Biosciences, Inc. Inhibidores de MEK
US7851484B2 (en) 2007-03-30 2010-12-14 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
EP2018854A1 (en) 2007-07-27 2009-01-28 Merz Pharma GmbH & Co. KGaA Novel combinations of neramexane for the treatment of neurodegenerative disorders
US7998976B2 (en) 2008-02-04 2011-08-16 Cytokinetics, Inc. Certain chemical entities, compositions and methods
CA2713864A1 (en) 2008-02-04 2009-08-13 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
CA2730473A1 (en) 2008-07-11 2010-01-14 Glaxo Group Limited Novel treatment
CN102264743B (zh) 2008-11-25 2015-02-11 罗彻斯特大学 Mlk抑制剂及其使用方法
EP2228054A1 (en) 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
AU2010262970A1 (en) 2009-06-19 2012-01-12 Knopp Neurosciences, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
WO2013151938A1 (en) 2012-04-02 2013-10-10 Cytokinetics, Inc. Methods for improving diaphragm function
BR112014025251B1 (pt) 2012-04-11 2021-03-02 Fady Malik uso de um ativador de troponina de músculo esquelético e composição compreendendo o mesmo
LT3137622T (lt) 2014-04-29 2022-04-25 Cytokinetics, Inc. Gyvybinio pajėgumo nykimo mažinimo būdai

Similar Documents

Publication Publication Date Title
JP2012193216A5 (enExample)
AU2014205529B2 (en) Methods and compositions for treatment of demyelinating diseases
JP2018193377A5 (enExample)
JP2014111603A5 (enExample)
JP2013505205A5 (enExample)
MX2014002459A (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
JP2015515475A5 (enExample)
JP2017503820A5 (enExample)
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
EA201491484A1 (ru) Фармацевтические композиции, содержащие диметилфумарат
PH12014500239A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP2016517883A5 (enExample)
MX382065B (es) Inhibidores de la quinurenina-3-monooxigenasa, sus composiciones farmacéuticas, y métodos para su uso.
JP2019524865A5 (enExample)
JP2013231087A5 (enExample)
JP2016530291A5 (enExample)
JP2017531033A5 (enExample)
JP2015083580A5 (enExample)
EA201692388A1 (ru) Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
JP2018530578A5 (enExample)
PE20091672A1 (es) Nueva dosificacion y formulacion
JP2014507475A5 (enExample)
JP2014521641A5 (enExample)
JP2017505809A5 (enExample)
MX380070B (es) Una composición farmacéutica que comprende amlodipino, valsartán y rosuvastatina.